TL1A inhibitors in inflammatory bowel disease: A systematic review of phase 2 clinical trials
Background: Tumor necrosis factor-like ligand 1A (TL1A) (TNFSF15) signals through DR3 to drive both mucosal inflammation and intestinal fibrosis. Three anti-TL1A antibodies (tulisokibart, afimkibart, and duvakitug) have completed Phase 2 trials in inflammatory bowel disease (IBD). We performed a systematic review (SR)...